^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD8 expression

    i
    Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
    Entrez ID:
    925
    Related biomarkers:
    Expression
    Others
    19h
    Predictive significance of MPT-driven necrosis-related genes signature in gastric cancer and their impact on the tumor microenvironment. (PubMed, Clin Transl Oncol)
    This study highlights the importance of MPTDN-related signatures in predicting GC prognosis and guiding therapeutic decisions.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression
    1d
    Therapeutic potential of Xihuang Pill in colorectal cancer: Metabolomic and microbiome-driven approaches. (PubMed, Front Pharmacol)
    In this study, mice harboring CT26 tumors were divided into four groups, each administered with either XHP monotherapy, 5-fluorouracil (5-FU), or a combination of both...This study delineates a potential mechanism by which XHP inhibits CRC tumorigenesis through modulating the gut microbiota, serum metabolites, and reshaping the tumor immune microenvironment in a murine CRC model. These findings contribute to a more profound understanding and potentially broaden the clinical utility of XHP in oncology.
    Journal • Metabolomic study
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    CD8 expression • FOXP3 expression
    |
    5-fluorouracil
    1d
    Single-Nucleus and Spatial Transcriptome Profiling Delineates the Multicellular Ecosystem in Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy. (PubMed, Adv Sci (Weinh))
    PD-1+CD8+ Tex-int accumulated in the TLS vicinity and disseminated throughout the tumor microenvironment, demonstrating potential as an effective biomarker for HAIC-based treatment in HCC. This study provides valuable resources and biological insights in the cellular underpinnings of HAIC treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • GZMK (Granzyme K)
    |
    CD8 expression
    2d
    The role of IL‑17, IFN‑γ, 4‑1BBL and tumour‑infiltrating lymphocytes in the occurrence, development and prognosis of pancreatic cancer. (PubMed, Oncol Lett)
    Furthermore, patients with pancreatic cancer with higher expression levels of CD3, CD8, CD56, IFN-γ and 4-1BBL exhibited longer survival, whereas those with higher expression of IL-17 had a shorter survival time. The expression levels of CD3, CD8, CD56, cytokines IL-17 and IFN-γ, and costimulatory molecule 4-1BBL were revealed to be related to the degree of differentiation, Tumour-Node-Metastasis staging and the prognosis of pancreatic cancer, and may serve as novel immunological indicators for evaluating the condition and treatment effectiveness in patients with pancreatic cancer.
    Journal • Tumor-infiltrating lymphocyte • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL17A (Interleukin 17A)
    |
    CD8 expression
    3d
    Downregulation of MHC-I on melanoma cells and decreased CD8+ T-cell infiltration are associated with metastatic spread and resistance to immunotherapy. (PubMed, Lab Invest)
    Furthermore, MHC-I downregulation and decreased infiltration with CD8+ T-cells is also associated with resistance to ICI. Our results suggest that analyses of MHC-I expression and CD8+ T-cell infiltration patterns could serve as future biomarkers to guide the decision to treat patients in early stages of melanoma with ICI.
    Journal • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression
    6d
    Queensland COVID-19 Vaccination (QoVAX) Safety and Efficacy Trial Program: Mixed Dose 1 and 2 Study (ACTRN12621001524886)
    P=N/A, N=2000, Completed, Metro North Hospital and Health Service | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • IL10 (Interleukin 10) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • GZMB (Granzyme B) • IL18 (Interleukin 18) • IL17A (Interleukin 17A) • IL1A (Interleukin 1, alpha) • IL23A (Interleukin 23 Subunit Alpha) • PRF1 (Perforin 1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • IL33 (Interleukin 33)
    |
    CD8 expression
    9d
    Human dose-escalation study of PET imaging CD8+ T-cell infiltration in solid malignancies with [68Ga]Ga -NODAGA-SNA006. (PubMed, Eur J Nucl Med Mol Imaging)
    The use of [68Ga]Ga-NODAGA-SNA006 is safe, feasible, and well tolerated. [68Ga]Ga-NONAGA-SNA006 PET imaging can accurately detect CD8 expression inside tumors with favorable pharmacokinetics, thus providing a feasible method for noninvasive quantitative assessment of CD8+ T-cell tumor infiltration and monitoring the response to immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression
    9d
    JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia. (PubMed, EMBO Mol Med)
    Skin biopsies from EGFR inhibitor-treated and cicatricial alopecia patients revealed an active JAK-STAT1 signaling signature along with upregulation of antigen presentation and downregulation of key components of the EGFR pathway. Our findings offer molecular insights and highlight a mechanism-based therapeutic strategy for addressing chronic folliculitis associated with EGFR-inhibitor anti-cancer therapy and cicatricial alopecia.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • JAK1 (Janus Kinase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    CD8 expression • IFNG expression
    11d
    Survival Impacts of Mitochondrial Status in Esophageal Squamous Cell Carcinoma Patients. (PubMed, Ann Surg Oncol)
    A low Mito-score before NAC had a significant survival impact in ESCC patients, especially in those with advanced disease. Mitochondrial status might be associated with tumor aggressiveness and responsiveness to NAC, thereby possibly affecting the survival outcomes of ESCC patients.
    Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    CD8 expression
    11d
    Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma. (PubMed, Oral Oncol)
    Our studies demonstrate that the small molecule MIF inhibitor CPSI-1306 potently inhibits T cell immunosuppression in the tumor microenvironment and reduces tumor growth in HNSCC. These studies open a novel therapeutic option for modulating anti-tumoral T cell immunity to improve HNSCC outcomes by targeting MIF.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • MIF (Macrophage Migration Inhibitory Factor) • GZMB (Granzyme B)
    |
    EGFR expression • CD8 expression
    13d
    Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P2, N=76, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • GZMB (Granzyme B) • IL17A (Interleukin 17A)
    |
    CD8 expression
    |
    Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • urelumab (BMS-663513)
    13d
    IDO1 Expression and CD8+ T-Cell Levels Are Useful Prognostic Biomarkers in Preoperative Gastric Cancer Specimens Before Neoadjuvant Chemotherapy. (PubMed, Appl Immunohistochem Mol Morphol)
    Overexpression of IDO1 and lower CD8+ T-cell levels were associated with poor survival in patients with gastric cancer who received neoadjuvant chemotherapy, and overexpression of IDO1 were associated with the poor tumor response. Our data suggest that IDO1 and CD8 testing of biopsy specimens might be a simple and effective prognostic biomarker for gastric cancer, and IDO1 could predict efficacy of neoadjuvant chemotherapy in gastric cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IDO1 (Indoleamine 2,3-dioxygenase 1)
    |
    PD-L1 expression • CD8 expression • IDO1 expression • IDO1 overexpression
    14d
    The Roles of Vitamin D Receptor (VDR) and CD8+ T-Lymphocytes in Acral and Mucosal Melanoma Invasion Depth. (PubMed, J Cutan Pathol)
    The role of VDR and CD8+ T-lymphocytes are inversely associated with melanoma depth in acral melanoma, while only VDR is associated with melanoma depth in mucosal melanoma.
    Journal
    |
    CD8 (cluster of differentiation 8) • VDR (Vitamin D Receptor)
    |
    CD8 expression
    14d
    Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma. (PubMed, EBioMedicine)
    Adjuvant R-CVP and elevated intratumoural CD8 expression were independently associated with sustained disease control after radiotherapy in ESFL.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8)
    |
    CD8 expression • BCL2 translocation
    |
    Rituxan (rituximab) • cyclophosphamide • vincristine
    15d
    Tumor growth suppression in adoptive T cell therapy via IFN-γ targeting of tumor vascular endothelial cells. (PubMed, Theranostics)
    Early targeting of tumor vascular endothelial cells by IFN-γ led to endothelial regression, reduced perfusion, and tumor hypoxia/necrosis (Day 4.5-7). These findings highlight the critical role of T cell-derived IFN-γ action on endothelial cells early in ACT, emphasizing its dynamic influence on the tumor microenvironment, and offering insights into addressing antigen escape.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    CD8 expression • IFNG expression
    15d
    JCXH-105-021: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (clinicaltrials.gov)
    P2, N=460, Recruiting, Immorna Biotherapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    CD8 expression
    16d
    The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy. (PubMed, Front Immunol)
    All in all, our results highlight NK cells and innate CD8 T-cells harboring cytotoxic content, as well as global downregulation of PD-1-expression on effector T-cells, as potential predictive functional signatures for successful TFR in CML. Considering innate CD8 T-cells, further investigations are needed to determine whether their possible contributory role in cancer surveillance in CML could be extended to other cancers, and also whether their targeting by immune cheek-point inhibitors could enhance their anti-tumoral functions.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PRF1 (Perforin 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    PD-1 expression • CD8 expression
    20d
    Intestinal IFNα4 promotes 15-HETE diet-induced pulmonary hypertension. (PubMed, Respir Res)
    Our data reveal a novel gut-lung axis driven by 15-HETE in PH.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • IFNA1 (Interferon Alpha 1)
    |
    CD8 expression
    20d
    5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells. (PubMed, Neoplasia)
    DAC treatment increased immunogenicity and decreased proliferation in HNSCC cells while enhancing expression of co-stimulatory ICM GITR and OX40. We propose low dose DAC treatment as a adjuvant to immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator) • CD27 (CD27 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    PD-1 expression • CD8 expression • CD8 positive
    |
    decitabine
    20d
    Magnesium-related gene ITGAL: a key immunotherapy predictor and prognostic biomarker in pan-cancer. (PubMed, Front Pharmacol)
    ITGAL is remarkably associated with CD8+T cells and crucial in the tumor immune microenvironment of pan-cancer. Furthermore, our findings may provide a targeted anti-tumor strategy for ITGAL by influencing the tumor immune microenvironment.
    Journal • IO biomarker • Pan tumor
    |
    CD8 (cluster of differentiation 8) • ITGAL (Integrin Subunit Alpha L)
    |
    CD8 expression
    21d
    Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity. (PubMed, bioRxiv)
    ANT308 decreased CREB phosphorylation, a downstream signaling pathway of the VIP receptor, and stimulated granzyme B and perforin expression in CD8+ T cells from AML patients. Combining in silico modeling, in vitro T cell activation properties, and in vivo anti-leukemia activity has identified promising VIP-R antagonist candidates for further development as novel immunotherapies for AML, especially for patients with relapsed disease.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • PRF1 (Perforin 1)
    |
    CD8 expression
    21d
    SLC2A3 promotes head and neck squamous cancer developing through negatively regulating CD8+ T cell in tumor microenvironment. (PubMed, Sci Rep)
    SLC2A3 is associated with changes in the TME and prognostic indicators. Moreover, high SLC2A3 expression in CD8+ T cells may drive cell death through ferroptosis, fostering tumor progression.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 overexpression • CD8 expression
    21d
    The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade. (PubMed, Biomol Biomed)
    Importantly, combining antigen expression, processing, presentation, and recognition features provides superior predictive power compared to TMB alone. This integrated approach could improve treatment outcome predictions and advance personalized immunotherapy strategies.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    TMB-H • CD8 expression
    21d
    Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy. (PubMed, Cancer Immunol Res)
    In murine tumor models, both genetic and pharmaceutical suppression of WNT7A led to increased MHC-I levels on tumor cells, and consequently enhanced the infiltration and functionality of CD8+ T cells, which bolstered antitumor immunity and improved the effectiveness of immune checkpoint blockade therapy. These findings have elucidated the intrinsic mechanisms of WNT7A-induced immune suppression, suggesting that therapeutic interventions targeting WNT7A hold promise for enhancing the efficacy of immunotherapy.
    Journal • Checkpoint inhibition • IO biomarker • Checkpoint block
    |
    CD8 (cluster of differentiation 8) • WNT7A (Wnt Family Member 7A) • FZD5 (Frizzled Class Receptor 5)
    |
    CD8 expression
    21d
    Higher Expression of Ku80 and Ku70 Indicates Hotter Tumor Immune Microenvironment in Hepatocellular Carcinoma and Better CTL-Centered Immunotherapy. (PubMed, J Inflamm Res)
    Higher Ku70/Ku80 expression indicated an immune-hot infiltration signature in HCC. Patients with increased Ku70/Ku80 expression and high CD8+CTL signatures may potentially benefit from CTL-centered immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression • CD8-H
    22d
    Setdb1-loss induces type-I interferons and immune clearance of melanoma. (PubMed, Cancer Immunol Res)
    Together, these results provide key in vivo evidence of a critical role for Setdb1 and type-I interferons in generating an inflamed tumor microenvironment, and potentiating tumor-cell intrinsic immunogenicity in melanoma. This study further emphasizes regulators of ERV expression and type-I interferon expression as potential therapeutic targets for augmenting anti-cancer immune responses.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1)
    |
    CD8 expression
    24d
    A Case of Abscessing Ileocecal Monomorphic Epitheliotropic Intestinal T-cell Lymphoma. (PubMed, Cureus)
    The proliferation index Ki-67 was evaluated as high, being positive in more than 70% of the tumor cells. The patient died 39 days after the initial onset of symptoms.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1)
    |
    CD8 expression • NCAM1 expression
    25d
    Expression of senescence-related CD161 promotes extranodal NK/T cell lymphoma by affecting T cell phenotype and cell cycle. (PubMed, Mol Med)
    CD161 may inhibit ENKTL tumor development by regulating cell cycle and T-cell phenotype.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • MMP1 (Matrix metallopeptidase 1) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    |
    CD8 expression • CD4 expression
    25d
    MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response. (PubMed, Cancer Lett)
    Thus, the therapeutic effectiveness appeared to largely depend on cancer-cell MHC-I expression, triggering CD8 T cell effector memory-driven responses against tumor cell antigens. Identifying the differential RT response to MHC-I induction may serve as a predictive marker for stratifying patients that are most likely to benefit from this combination therapy.
    Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • SMAD4 (SMAD family member 4) • B2M (Beta-2-microglobulin) • NLRC5 (NLR Family CARD Domain Containing 5) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    KRAS mutation • KRAS G12D • KRAS G12 • CD8 expression
    25d
    High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. (PubMed, Breast Cancer Res Treat)
    These data support the hypothesis that in early-stage TNBC, high GR expression is significantly associated with infiltration of immunosuppressive regulatory T cells, suggesting a tumor-intrinsic role in shaping the immunosuppressive immune cell milieu. Furthermore, suppression of GR activity may regulate the tumor immune microenvironment and improve long-term outcomes in GR-high TNBC.
    Journal
    |
    CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3) • NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1) • BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)
    |
    CD8 expression
    26d
    Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy. (PubMed, World J Gastrointest Surg)
    ICIs in combination with bevacizumab can not only improve the patient's prognosis but also yield safe and controllable adverse drug reactions in patients suffering from MSS/pMMR advanced CRC after failure to a 1st-line therapy.
    Journal • MSi-H Biomarker • IO biomarker • Metastases
    |
    MSI (Microsatellite instability) • CD8 (cluster of differentiation 8)
    |
    MSI-H/dMMR • CD8 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tyvyt (sintilimab) • irinotecan • leucovorin calcium
    30d
    IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells. (PubMed, Nat Commun)
    Mechanistically, IL-12 is essential for the expression of NKG2A on CD8 T cells in a CD40/CD40L- dependent manner, in conjunction with TCR stimulation. Our study thus reveals that NKG2A is induced by IL-12 on human tumor-reactive CD8 T cells exposed to a TGF-β-rich environment, highlighting an underappreciated immuno-regulatory feedback loop dependent on IL-12 stimulation.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HLA-E (Major Histocompatibility Complex, Class I, E) • TGFB1 (Transforming Growth Factor Beta 1) • ITGAE (Integrin Subunit Alpha E) • CD40LG (CD40 ligand) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    CD8 expression
    30d
    Chaperonin-containing TCP1 subunit 6A inhibition via TRIM21-mediated K48-linked ubiquitination suppresses triple-negative breast cancer progression through the AKT signalling pathway. (PubMed, Clin Transl Med)
    Chaperonin TCP1 subunit 6A (CCT6A) plays an oncogenic role in triple-negative breast cancer (TNBC) through the AKT signaling pathway. TRIM21 facilitated K48-linked ubiquitination-mediated degradation of CCT6A, thereby impeding TNBC progression. Our study collectively underscores the potential of Ipatasertib in conjunction with anti-PD1 therapy as a promising strategy to counteract CCT6A/AKT hyperactivity-driven TNBC progression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • TRIM21 (Tripartite Motif Containing 21)
    |
    CD8 expression • PTPRC expression
    |
    ipatasertib (RG7440)
    1m
    Application of integrin subunit genes in pancreatic cancer and the construction of a prognosis model. (PubMed, J Gastrointest Oncol)
    Further, the proportions of T cells and cluster of differentiation 8 (CD8) T cells, and the expression levels of immune checkpoints, such as cluster of differentiation 274 (CD274) and lymphocyte activating gene 3 (LAG3), differed significantly between the two risk groups. The eight identified KDE-ITGs in PAAD were used to establish a new prognosis model, which might have clinical application, especially in immunotherapy.
    Journal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
    |
    CD8 expression
    1m
    Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. (PubMed, Sci Immunol)
    In hepatocellular carcinoma, DHHC9 expression correlated with TIM-3 expression in CD8+ T cells and NK cells, and high DHHC9 expression was associated with shorter survival in patients with high TIM-3. These findings demonstrate that palmitoylation of TIM-3 catalyzed by DHHC9 promotes its stability, resulting in immune exhaustion and impaired antitumor immunity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    CD8 expression • HAVCR2 expression
    1m
    Clinical and immunological characteristics of high-risk double-hit multiple myeloma. (PubMed, BMC Cancer)
    In vitro we have shown that the addition of TGF-β1 antibody or CD38 antibody can effectively inhibit the proportion of CD38high Tregs. This study describes the characteristics of DHMM based on bicentric data, which is helpful to better provide theoretical support for the treatment of DHMM.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-1 expression • CD8 expression • CD38 overexpression
    1m
    TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction. (PubMed, J Immunother Cancer)
    Our results uncover a novel mechanism of PD-1 regulation, and identify a pharmacologically tractable target whose inhibition suppresses PD-1 abundance and T cell dysfunction.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    PD-1 expression • CD8 expression
    1m
    LAG-3 Expression, γδ-T cell/MHC-I Interactions and Prognosis in Merkel Cell Carcinoma. (PubMed, Lab Invest)
    Overall, LAG-3 is expressed in MCC infiltrates and is prognostic in pre-immunotherapy MCC, suggesting a potential role for LAG-3 inhibition in MCC. Additionally, CD8 and γδ-T cells may play a critical role in the response to MCC, and γδ-T cell density may represent a novel biomarker in MCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
    |
    PD-L1 expression • CD8 expression • LAG3 expression • CD8-H
    1m
    Prediction of Treatment Response Based on Nutritional Status and Tumor Immunity in Oropharyngeal Cancer Patients Treated With Chemoradiotherapy. (PubMed, Cancer Diagn Progn)
    A combined risk score incorporating clinical, nutritional, and immune factors can improve the prediction of treatment outcomes for OPC patients. This risk stratification may enable personalized treatment plans and improve ΟS rates.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression • CD8 positive
    1m
    Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide (ASH 2024)
    Conclusions : Tal-DP exhibits a deep, long-term impact on efficacy through complementary mechanisms of action and may be especially beneficial in pts with prior BsAb exposure, who typically have unfavorable BL immune profiles. Ongoing analyses of tec-DP from MajesTEC-2 (NCT04722146) will be presented.
    Clinical • PK/PD data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    CD38 expression • CD8 expression • LAG3 expression
    |
    Darzalex (daratumumab) • pomalidomide • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    Highly-Multiplexed Immunofluorescence PhenoCycler Panel for Murine FFPE Yields Insight into Tumor Microenvironment Immunoengineering. (PubMed, Lab Invest)
    Delivery of IFNγ, in addition to 4-1BBL and IL-12, further increased markers of antigen presentation on tumor cells and intratumoral antigen-presenting cells but also promoted greater expression of checkpoint marker PD-L1 and closer associations between intratumoral CD8 T cells and PD-L1-expressing tumor cells. These findings help to explain the benefits of 4-1BBL and IL-12 delivery while offering additional mechanistic insights into the limitations of IFNγ therapeutic efficacy.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    PD-L1 expression • CD8 expression
    2ms
    Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells. (PubMed, Nat Commun)
    Similarly, EP4 and EP2 are induced upon macrophage activation, and PGE2 downregulates c-Myc and OXPHOS in M1-like macrophages. These results suggest that PGE2-EP4/EP2 signaling impairs both adaptive and innate immunity in TME by hampering bioenergetics and ribosome biogenesis of tumor-infiltrating immune cells.
    Journal • Immune cell
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha)
    |
    CD8 expression